CORT (Corcept Therapeutics) Short-Term Debt to Capital

Corporate company logo of Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT) faces acute patent disputes regarding Korlym, although new developments are reducing its reliance on a single product. The company dominates a niche cortisol therapy segment, successfully resisting pressure from generic manufacturers. The price action characteristic (separate_debt_short_eq) recorded a value of 0.00. The business relies on a team of top endocrinologists with access to cutting-edge laboratories for the creation of unique medications.

Ratio of Short-Term Indebtedness to Capital: Corcept (CORT) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Corcept Therapeutics

- stock quotes and analyst forecast:
Stock Price Corcept|CORT - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Corcept Therapeutics Inc.|CORT - Enterprise Value
- book capitalization information:
Net Assets per Single Share Corcept Therapeutics|CORT - Accounting Value of Company|Market Value to Book Value Ratio corcept.com|CORT - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Corcept Therapeutics|CORT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Corcept Therapeutics Incorporated|CORT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Corcept Therapeutics Inc.|CORT - Company Long-Term Liabilities|Company Short-Term Debts Corcept Therapeutics|Quick Liquidity Indicator corcept.com
- company profitability and valuation multiples indicators:
CORT - Profit After Payment of Taxes
Fundamental valuation:CORT Corcept
Brand item of Corcept Therapeutics Inc.

Corcept Therapeutics' dependence on Korlym sales and generic risks necessitate strict liquidity control to fund new clinical trials. By analyzing the short-term debt-to-equity trend, an investor assesses the ratio of loans under one year to shareholders' equity, which helps identify hidden cash gaps and determine the stability of the company's financial leverage.

Competitors of Corcept Therapeutics

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital RYTM (Rhythm Pharmaceuticals)|Short-Term Debt to Capital akerotx.com AKRO|MTSR - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Capital CTCX (Carmell Corporation)|LUMO - Short-Term Debt to Equity Ratio|ONVO - Short-Term Debt to Equity|Current Liabilities to Capital Radius Recycling Inc.